Gene editing and CRISPR-based therapies by Editas Medicine

  • Alena Volkova
  • 12.11.2026
Editas Medicine reports potential of EDIT-401 therapy for hyperlipidemia in fresh study
Editas Medicine unveiled new preclinical data for its investigational therapy EDIT-401, focusing on durability in treating hyperlipidemia, at AHA2026. The findings suggest that EDIT-401 could ...
  • Oksana Koneva
  • 09.11.2026
Editas Medicine reports third quarter 2026 results and business updates
Editas Medicine has announced its financial results and business developments for the third quarter of 2026. The update was shared through an official press release and includes information on ...
  • Yaroslav Dmytrenko
  • 03.11.2026
Preclinical results on lead candidate EDIT-401 to be unveiled by Editas Medicine at AHA event
Editas Medicine announced that it will present new preclinical data on EDIT-401, its lead in vivo development candidate, at this year’s American Heart Association Scientific Sessions in Chicago. ...
  • Daria Chernytska
  • 14.10.2026
Editas Medicine announces poster presentations at ESGCT 33rd Annual Congress and investor conference participation
Editas Medicine has revealed plans to present scientific posters at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress. The company also announced its participation in an ...
  • Pavlo Kot
  • 08.10.2026
Editas Medicine gains nod for clinical trial of EDIT-401 in cardiovascular disease
Editas Medicine has received authorization to begin its first in human clinical trial of EDIT-401, targeting patients with hyperlipidemia. This development marks a notable milestone for the ...
  • Yaroslav Dmytrenko
  • 08.09.2026
Editas Medicine appoints Dan Ory as chief medical officer
Editas Medicine has announced the appointment of Dan Ory, M.D., as its new chief medical officer. The company shared the leadership change in an update, adding that additional details are ...
  • Igor Krasulya
  • 05.08.2026
Editas Medicine delivers business updates alongside second quarter 2026 financial release
Editas Medicine has released its financial results for the second quarter of 2026, alongside a series of business updates. The company outlined its progress across therapeutic areas, including ...
  • Oleg Tkachenko
  • 29.06.2026
Editas Medicine team joins J.P. Morgan Corporate Challenge to boost workplace collaboration
Editas Medicine employees recently took part in the annual J.P. Morgan Corporate Challenge, strengthening relationships beyond the workplace. The event provided staff with an opportunity to ...
  • Artem Shendetskii
  • 24.06.2026
Editas Medicine to present future-shaping innovations in genetic medicine at ECB2026
Editas Medicine is preparing to deliver a keynote lecture at the upcoming European Congress on Biotechnology, focusing on the evolution of genetic medicines. The presentation, titled 'A Walk ...
  • Anastasiia Chabaniuk
  • 12.06.2026
Editas Medicine CEO to join MIT panel on pipeline prioritization at Longwood Healthcare Leaders event
Editas Medicine announced that its President and CEO, Gilmore O’Neill, will participate in the upcoming Longwood Healthcare Leaders MIT CEO 2026 Meeting. He is scheduled to join industry peers ...
  • Mikhail Vnuchkov
  • 28.05.2026
Editas Medicine adjusts agenda at key investor event
Editas Medicine has updated the scheduled presentation time for its upcoming appearance at an investor conference. The company directed stakeholders to its full press release for detailed ...
  • Anastasiia Chabaniuk
  • 27.05.2026
Editas Medicine presents new preclinical data on EDIT-401 at EASCongress2026
Editas Medicine presented new preclinical data this week at EASCongress2026, focusing on the progress of its lead in vivo development candidate, EDIT-401. The company provided details supporting ...
  • Olga Shendetskaya
  • 21.05.2026
Editas Medicine prepares to present in vivo candidate data at EAS Congress in Athens
Editas Medicine will attend the 94th European Atherosclerosis Society Congress in Athens next week, where it plans to present new preclinical findings on its lead in vivo development candidate, ...